Literature DB >> 26423637

Using Administrative Data to Examine Health Disparities and Outcomes in Neurological Diseases of the Elderly.

Allison W Willis1,2,3,4.   

Abstract

The fields of neurodegenerative disease and dementia research have grown considerably in the last several decades. Due to tremendous efforts of basic and clinical research scientists, we know a great deal about dementia risk factors and have multiple treatment options. Clinician recognition of cognitive impairment has increased considerably, national policies which support screening for and documenting cognitive dysfunction now exist, and public awareness of neurodegenerative disease has never been greater. These conditions promote (and demand) the growth of translational epidemiology and health services research, which focuses on examining outcomes in groups of individuals as a function of health care experiences. This review discusses the use of administrative data to answer health care outcomes and disparities questions in dementia. Of particular interest are publically available datasets that contain varying amounts of diagnostic, clinical, pharmacy, and patient information. Methodological challenges that are frequently encountered and must be understood to minimize biased inference are also discussed.

Entities:  

Keywords:  Administrative data research; Cognitive impairment; Dementia; Epidemiology; Health services research; Parkinson disease

Mesh:

Year:  2015        PMID: 26423637     DOI: 10.1007/s11910-015-0595-4

Source DB:  PubMed          Journal:  Curr Neurol Neurosci Rep        ISSN: 1528-4042            Impact factor:   5.081


  32 in total

1.  Late-life depression and cardiovascular disease burden: examination of reciprocal relationship.

Authors:  Namkee G Choi; Jinseok Kim; C Nathan Marti; G John Chen
Journal:  Am J Geriatr Psychiatry       Date:  2014-04-19       Impact factor: 4.105

2.  Skilled nursing facility admissions of nursing home residents with advanced dementia.

Authors:  Jane L Givens; Susan L Mitchell; Sylvia Kuo; Pedro Gozalo; Vince Mor; Joan Teno
Journal:  J Am Geriatr Soc       Date:  2013-10-01       Impact factor: 5.562

3.  The role of accommodations in poststroke disability management.

Authors:  Lesli E Skolarus; James F Burke; Vicki A Freedman
Journal:  J Gerontol B Psychol Sci Soc Sci       Date:  2014-11       Impact factor: 4.077

Review 4.  Genetic studies of quantitative MCI and AD phenotypes in ADNI: Progress, opportunities, and plans.

Authors:  Andrew J Saykin; Li Shen; Xiaohui Yao; Sungeun Kim; Kwangsik Nho; Shannon L Risacher; Vijay K Ramanan; Tatiana M Foroud; Kelley M Faber; Nadeem Sarwar; Leanne M Munsie; Xiaolan Hu; Holly D Soares; Steven G Potkin; Paul M Thompson; John S K Kauwe; Rima Kaddurah-Daouk; Robert C Green; Arthur W Toga; Michael W Weiner
Journal:  Alzheimers Dement       Date:  2015-07       Impact factor: 21.566

5.  Cognitive and Brain Profiles Associated with Current Neuroimaging Biomarkers of Preclinical Alzheimer's Disease.

Authors:  Florent L Besson; Renaud La Joie; Loïc Doeuvre; Malo Gaubert; Florence Mézenge; Stéphanie Egret; Brigitte Landeau; Louisa Barré; Ahmed Abbas; Meziane Ibazizene; Vincent de La Sayette; Béatrice Desgranges; Francis Eustache; Gaël Chételat
Journal:  J Neurosci       Date:  2015-07-22       Impact factor: 6.167

6.  Mobility device use in older adults and incidence of falls and worry about falling: findings from the 2011-2012 national health and aging trends study.

Authors:  Nancy M Gell; Robert B Wallace; Andrea Z LaCroix; Tracy M Mroz; Kushang V Patel
Journal:  J Am Geriatr Soc       Date:  2015-05-06       Impact factor: 5.562

7.  Risk of pneumonia in new users of cholinesterase inhibitors for dementia.

Authors:  Edward Chia-Cheng Lai; Monera B Wong; Isao Iwata; Yinghong Zhang; Cheng-Yang Hsieh; Yea-Huei Kao Yang; Soko Setoguchi
Journal:  J Am Geriatr Soc       Date:  2015-04-27       Impact factor: 5.562

8.  Deep brain stimulation plus best medical therapy versus best medical therapy alone for advanced Parkinson's disease (PD SURG trial): a randomised, open-label trial.

Authors:  Adrian Williams; Steven Gill; Thelekat Varma; Crispin Jenkinson; Niall Quinn; Rosalind Mitchell; Richard Scott; Natalie Ives; Caroline Rick; Jane Daniels; Smitaa Patel; Keith Wheatley
Journal:  Lancet Neurol       Date:  2010-04-29       Impact factor: 44.182

Review 9.  Measuring frailty using claims data for pharmacoepidemiologic studies of mortality in older adults: evidence and recommendations.

Authors:  Dae Hyun Kim; Sebastian Schneeweiss
Journal:  Pharmacoepidemiol Drug Saf       Date:  2014-06-24       Impact factor: 2.890

10.  Functional impairment, healthcare costs and the prevalence of institutionalisation in patients with Alzheimer's disease and other dementias.

Authors:  Jerrold Hill; Howard Fillit; Simu K Thomas; Sobin Chang
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

View more
  4 in total

Review 1.  Secondary Analysis of Existing Datasets for Dementia and Palliative Care Research: High-Value Applications and Key Considerations.

Authors:  Lauren J Hunt; See J Lee; Krista L Harrison; Alexander K Smith
Journal:  J Palliat Med       Date:  2017-12-21       Impact factor: 2.947

2.  Generation and validation of algorithms to identify subjects with dementia using administrative data.

Authors:  Jacopo C DiFrancesco; Alessandra Pina; Giorgia Giussani; Laura Cortesi; Elisa Bianchi; Luca Cavalieri d'Oro; Emanuele Amodio; Alessandro Nobili; Lucio Tremolizzo; Valeria Isella; Ildebrando Appollonio; Carlo Ferrarese; Ettore Beghi
Journal:  Neurol Sci       Date:  2019-06-12       Impact factor: 3.307

3.  Neuroprotective effect of antioxidant compounds.

Authors:  Rachid Skouta
Journal:  Neural Regen Res       Date:  2016-04       Impact factor: 5.135

4.  Assessing the Antioxidant Properties of Larrea tridentata Extract as a Potential Molecular Therapy against Oxidative Stress.

Authors:  Rachid Skouta; Karla Morán-Santibañez; Carlos A Valenzuela; Abimael H Vasquez; Karine Fenelon
Journal:  Molecules       Date:  2018-07-23       Impact factor: 4.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.